The reproductive health devices market includes Endometrial Ablation devices, Female Sterilization devices, Reversible Contraceptive devices and Assisted Reproductive Technology devices. Reversible contraceptive devices are used as birth control to prevent unwanted pregnancy. GlobalData uses proprietary data and analytics to provide a comprehensive report on the reversible contraceptive devices devices market, including market shares of different players within Portugal. Buy the latest report here.
Smarter leaders trust GlobalData
In 2021, GlobalData’s Market Model methodology determined that the leading player in the reversible contraceptive devices market in Portugal was Bayer followed by HLL Lifecare, Allergan Aesthetics, CooperSurgical, Meril Life Sciences and Pregna International.
Reversible Contraceptive Devices are inserted or implanted into women of child-bearing age, often for long periods of time. This includes Intrauterine Devices (IUDs), Diaphragms and Implants.
Following the widespread disruption resulting from the COVID-19 pandemic to the broader medical devices market during 2020 and 2021, the value of the reversible contraceptive devices devices market within Portugal was expected to be over $3m in 2021.
For the latest complete market share analysis of reversible contraceptive devices device market in Portugal, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
